PDGFC protein expression was analyzed by immunohistochemistry, and the relationship between PDGFC protein expression and clinicopathologic features was investigated in 245 patients with stage I-III CRC. PDGFC mRNA expression in cancer tissues was significantly higher in patients with distant metastases than in those without metastases (P = 0.016). PDGFC protein overexpression was associated with significantly worse overall and relapse-free survival (P < 0.0001 and P < 0.0001, respectively). Moreover, PDGFC protein overexpression was an independent risk factor for CRC recurrence (relative risk = 3.395, 95% confidence interval = 1.895 -6.081, P < 0.001). In the present study, PDGFC overexpression appeared to be predictive of recurrence and poor prognosis in patients with CRC.
Introduction
Colorectal cancer (CRC) is one of the most prevalent cancers in the world. It is the third most common cancer and the second most common cause of cancer-related mortality worldwide [1] . The mortality rate of this malignancy has changed little over the last 30 years despite advances in the understanding of the pathogenesis of this cancer at the molecular level. Approximately 20% -40% of patients with CRC who undergo curative surgery develop local recurrence or distant metastases, resulting in shorter survival [2] . The tumor node metastasis (TNM) classification proposed by the International Union Against Cancer remains an important indicator of prognosis and provides the basis for therapeutic decisionmaking [3] . However, the current TNM classification system is limited in that it cannot predict prognosis for individual patients. To improve the prognosis of CRC, there is a crucial need to explore cancer-related genes that can serve as predictive biomarkers for individualization of therapy [4] .
Concerning treatment, the introduction of targeted therapies, including the epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies cetuximab and panitumumab and the vascular epithelial growth factor (VEGF)-targeting monoclonal antibody bevacizumab, has improved the median survival of patients with metastatic CRC to approximately 24 months. Several pathways for tumor growth and tumor angiogenesis, including VEGF, fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) pathways that have been identified recently, have attracted substantial interest due to their potential clinical application [5, 6] .
The PDGF family is known to be associated with tumor growth and angiogenesis through activation of the receptor tyrosine kinases (RTKs) PDGF receptor (PDG-FR) isoforms alpha and beta. A number of studies illustrated the importance of PDGFA and PDGFB in the recruitment of tumor stroma in skin cancer, melanoma, breast cancer, and lung cancer [7] [8] [9] [10] . Conversely, PDG-FC is a multi-domain protein with a C-terminal domain capable of binding to and activating PDGFR [11, 12] . It is a potent mitogen for cells of mesenchymal origin, and its function as an inductor of liver fibrosis has been established [11] [12] [13] [14] . A tumor growth-promoting function through the recruitment of fibroblasts has occasionally been described for PDGFC in a melanoma model and in hepatocellular carcinoma [13, 15, 16] . Although several reports revealed that the expression of PDGFs is related to CRC, the role of PDGFC in cancer, especially CRC, is less well studied. Few studies have revealed the relationship between PDGFC expression and clinical outcome using samples from patients with CRC. Thus, this study aimed to identify the correlation between PDGFC expression and the prognosis of patients with CRC.
Methods

Patients
Primary tumors from 262 consecutive patients who underwent surgical resection for CRC between 2002 and 2006 at Tokyo Medical and Dental University Hospital were included in our study. All patients provided written informed consent to participate in this study, and the Institutional Review Board approved the study (approval number: 831). Samples from 85 patients with stage I-IV CRC were submitted for quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis, including samples from 9 patients with stage I CRC, 25 patients with stage II CRC, 34 patients with stage III CRC, and 17 patients with stage IV CRC. The median follow-up time was 48 months for these patients (range: 1 -66 months). Fourteen patients with stage I-III CRC experienced a relapse. We divided the 85 patients into two groups: the non-metastatic (stage I-III without recurrence, n = 54) and metastatic (stage I-III with recurrence and stage IV, n = 31) groups. patients received systemic chemotherapy and 6 received hepatic arterial infusion (HAI) chemotherapy. Fifty-two patients with relapse received the following treatment; radical resection of metastatic lesions for 16 patients, systemic chemotherapy for 15, systemic chemotherapy with HAI chemotherapy for 5, chemo-radiation therapy for 3, and supportive therapy or others for 13. The regimen of systemic chemotherapy included 5FU/LV, 5FU/ LV and oxaliplatin (FOLFOX), FOLFOX and bevacizumab, oral UFT/LV, oral UFT/LV and irinotecan (TE-GAFIRI), irinotecan alone, S-1 alone, and S-1/irinotecan (IRIS).
Quantitative RT-PCR
Total RNA collected from bulk samples of cancer tissues and adjacent non-neoplastic tissues was extracted and purified using an RNeasy mini kit (QIAGEN) with oncolumn DNase digestion according to the manufacturer instructions. For cDNA synthesis, 10 µg of total RNA was reverse-transcribed into cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to the manufacturer protocol. TaqMan gene expression assays (Applied Biosystems: PDGFC, Hs00211916_m1; β-actin, Hs99999903_m1) were used to determine the expression of PDGFC. β-Actin was used as an internal control. PCR was performed using the TaqMan Universal PCR Master Mix (Applied Biosystems) with 1 µL of cDNA in a 24-µL final reaction volume. The thermal cycling conditions were as follows: 50˚C for 2 min, 95˚C for 10 min, and 40 cycles of 15-s denaturation at 95˚C and 1-min annealing at 60˚C. All calculated concentrations of target genes were normalized to the amount of the endogenous reference by the comparative Ct method for relative quantification ( ∆∆Ct method) using Relative Quantification Study Software (7300 Sequence Detection System version 1.2.1; Applied Biosystems). Each assay was performed in duplicate.
Immunohistochemistry
Immunohistochemical studies of PDGFC expression were conducted using formalin-fixed, paraffin-embedded Clinical Significance of Platelet-Derived Growth Factor-C Expression in Colorectal Cancer
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JCT 13 surgical sections. Following deparaffinization in xylene and antigen retrieval by microwaving (Microwave-MI 77; Azumaya Corporation, Tokyo, Japan), pretreatment at 98˚C was performed for 30 min in a high pH target retrieval solution (Dako, Carpentaria, CA). The endogenous peroxidase activity was quenched by 15-min incubation in a mixture of 3% hydrogen peroxide solution in 100% methanol. After washing with phosphate-buffered saline (PBS), nonspecific binding was blocked by treating slides with 10% normal rabbit serum IgG (Nichirei Bioscience, Tokyo, Japan) for 10 min. Following washing with PBS, the specimens were incubated with a goat polyclonal antibody against human PDGFC (sc-182280; Santa Cruz Biotechnology, CA) at a 1:50 dilution overnight at 4˚C after 60-min incubation at room temperature. Sections were washed with 0.1% Tween 20/PBS thrice and incubated with peroxidase-labeled anti-goat antibody (Histofine Simple Stain Max PO(G); Nichirei Bioscience) for 30 min at room temperature. Peroxidase activity was detected via incubation with 0.02% 3,3'-diaminobenzidine tetrahydrochloride (Nichirei Bioscience) for 30 min.
The sections were counterstained with hematoxylin. PDGFC expression was graded by two independent observers. The semiquantitative assessment of PDGFC immunostaining included both the intensity (0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining, as compared with positive internal controls) and extent of staining (1, <10%; 2, 10% -40%; 3, 41% -70%; and 4, >71%). The scores were determined by the sum of the intensity grade and the extent of staining grade (range of scores, 1 -7).
Statistical Analysis
Statistical analyses of PDGFC expression were conducted using SPSS (version 17.0, SPSS Inc.) for Windows software. Differences between groups were estimated using the Mann-Whitney U test, the Wilcoxon signed-rank test, and the χ 2 test. Correlation was estimated using Spearman's rank correlation coefficient. Survival curves were estimated using the Kaplan-Meier method, and comparisons between curves were made using the log-rank test. Prognostic factors were estimated using univariate and multivariate analyses (Cox proportional hazards model). P < 0.05 denoted statistical significance.
Results
Expression of PDGFC mRNA in Cancer and Normal Tissues
Quantitative RT-PCR analyses of 85 patients with stage I-IV CRC revealed that PDGFC mRNA expression levels were significantly higher in cancer tissues than in adjacent noncancerous tissues (P < 0.001; Figure 1(a) ). The mRNA expression of PDGFC in cancer tissues was significantly higher in patients with distant metastases and recurrence (n = 31) than those without metastases (n = 54, P = 0.016; Figure 1(b) ). Concerning other clinicopathologic parameters, depth of tumor invasion (T1-T3 versus T4), lymphatic invasion, lymph node metastasis, and carcinoembryonic antigen (CEA) level before surgical resection (<5 ng/ml versus >5 ng/ml) were significantly associated with metastatic CRC (P = 0.002, P = 0.001, P < 0.001, and P < 0.001, respectively).
PDGFC Protein Expression in Cancer and Normal Tissues
The results obtained for PDGFC protein expression in
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CRC and normal colorectal epithelium are shown in Figure 2 . PDGFC expression was detected in the membrane and cytoplasm of cancer cells. There was no significant localization of staining in cancer tissues. In normal epithelial cells, 162 patients (74.3%) displayed no staining or only weak staining and 56 patients (25.6%) exhibited moderate to strong staining. A significant correlation between the staining score in cancer cells and staining in normal epithelium was observed in our study (P = 0.041). PDGFC mRNA expression was correlated with protein expression in the 85 patients who underwent RT-PCR analysis (correlation coefficient r = 0.247, P = 0.022; Figure 3 ).
High PDGFC Protein Expression Correlates with Clinicopathologic Variables and Survival
The experimental samples from patients without stage IV CRC that were used for immunohistochemical analysis were divided into two groups: the low expression (staining score ≤5, n = 144 [58.7%]) and high -expression groups (staining score ≥6, n = 101 [41.2%]). There were 26 patients (10.6%) with no staining or almost no staining in cancer cells. Table 1 shows PDGFC protein expression in cancer samples and the clinicopathologic data of 245 patients with stage I, II, or III CRC. The high expression group had significantly greater frequencies of lymphatic invasion (P = 0.032), venous invasion (P = 0.022), and elevated serum CEA levels (P = 0.049) than the low expression group. In addition, the high expression group showed tended to have a higher number of male patients (P = 0.022). There were no significant differences in the factors of TNM staging (depth and lymph node metastasis) between the low expression and high expression groups among these patients. The relapse-free survival (RFS) and overall survival (OS) rates were significantly lower (P < 0.0001 and P < 0.0001, respectively) in patients with high PDGFC protein expression than in those with low PDGFC protein expression (Figure 4) . Univariate analysis showed that the following factors were significantly associated with worse RFS: rectal cancer, moderately-or poorly-differentiated and other type of cancer, T4 tumor, lymphatic invasion, venous invasion, lymph node metastasis, an elevated CEA level, and high PDGFC expression ( Table 2) . Multivariate analysis using the Cox proportional hazards model indicated that lymph node metastasis and high PDGFC expression were associated with worse RFS (relative risk [RR] = 2.184, P = 0.012 and RR = 3.395, P < 0.001, respectively). Regarding OS, univariate analysis identified the following factors as significantly associated with worse OS: male, rectal cancer, moderately-or poorly-differentiated and other type of cancer, T4 tumor, lymphatic invasion, lymph node metastasis, an elevated CEA level, and high PDGFC expression ( Table 3 ). Multivariate analysis indicated that gender (RR = 2.900; P = 0.05), location (RR 2.136; P = 0.041), and PDGFC protein overexpression (RR = 3.374; P = 0.006) were independent risk factors for the prognosis of patients with CRC.
Discussion
In this study, we investigated the correlation between PDGFC expression and clinicopathologic features in patients with CRC at both the mRNA and protein levels. The expression of PDGFC in cancer tissues was significantly higher in patients in the metastatic group than in those in the non-metastatic group, suggesting that PDG-FC might contribute to metastasis in CRC. To determine whether PDGFC expression could predict the prognosis of patients with CRC after curative surgery, we performed immunohistochemical studies using samples from patients with stage I, II, or III disease. We found several significant correlations between PDGFC protein expression and clinicopathologic factors. Moreover, multivariate analysis indicated that PDGFC protein overexpression was an independent and significant prognostic factor for CRC recurrence after curative surgery. PDGFC is a mitogenic factor for cells of mesenchymal origin and appears to be involved in all three phases (inflammation, proliferation, and remodeling/maturation) of wound healing [11, [17] [18] [19] [20] [21] [22] . Several studies identified PDGFC as a potent antigenic factor, similar to VEGF and the classical PDGFs [11, [23] [24] [25] . Abnormalities in the PDGF/PDGFR system such as constitutive activation of PDGFR kinases, activating mutations of the PDGFR kinases, and autocrine signaling due to overexpression of PDGFs and the PDGFRs contribute to a number of human diseases, especially malignancies including osteosarcomas, lung carcinomas, gliomas, malignant astrocytomas, and medulloblastomas [26, 27] . Oncogenic transformation mediated by the autocrine PDGF loop occurs through activation of the ras/MAPK pathway, which increases cellular proliferation, and activation of the PI3K/ Akt pathway, which promotes cell survival [28] . The discovery that PDGFB is a v-sis homolog made PDGFB one of the earliest discovered oncogenes, connecting PDGF/ PDGFR to cellular transformation [29] . The finding that PDGFC acts similarly as PDGF-AB, the most mitogenic of all PDGFs [30] , as it activates both PDGFR-AA and PDGFR-AB, indicates a role for PDGFC as an oncogene [11, 31] . PDGFC induces tumor formation in nude mice, activates anchorage-dependent growth, and is a potent transforming growth factor in NIH/3T3 cells [32] . In vivo tumorigenesis may partially be explained by PDG-FC-mediated VEGF expression, promoting indirect stimulation of tumor angiogenesis. Moreover, it is known that PDGFC behaves in a paracrine manner to recruit cancer-associated fibroblasts (CAFs) and promotes angiogenesis and tumor growth. Anderberg et al. revealed the functional significance of paracrine PDGFC signaling in the recruitment of CAFs into experimental mouse me- [33] . Several tyrosine kinase pathways are activated by overexpressed PDGFC in cancer cells via autocrine pathways, thereby promoting tumor growth and anti-apoptosis. It is possible that tumors with PDGFC-mediated PDGF-receptor activation are sensitive to tyrosine kinase inhibitors [34] . Thus, although many studies suggest that PDGFC plays an important role in tumor growth, angiogenesis, and tumor microenvironment both in vivo and in vitro, its precise role in cancer and its impact on actual clinical outcomes remain unknown. In the present study, we observed that several clinical features were affected by the expression of PDGFC. This is the first study to demonstrate the relationship between PDGFC expression and prognosis in patients with CRC. Despite curative surgery for localized disease, approximately 40% of patients with CRC will eventually relapse [35] . Recently, some adjuvant chemotherapies for patients with CRC were indicated to be associated with improved cure rates after surgery [36] . Despite the efficacy of these chemotherapies, they are costly and associated with severe adverse effects. Therefore, there exists a need to identify patients who would benefit from adjuvant chemotherapy prior to treatment; molecular markers may provide important insight concerning this challenge [37, 38] , as these markers can be considered when selectClinical Significance of Platelet-Derived Growth Factor-C Expression in Colorectal Cancer
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ing the appropriate chemotherapy. Our study suggests that high PDGFC protein expression is predictive of recurrence after curative surgery for CRC. In the last decade, the development of novel therapies that target critical biological pathways has greatly expanded treatment options for patients with CRC and resulted in substantial improvements in survival [39] . PDGFC might be a useful biomarker to decide whether to use strong adjuvant chemotherapy in patients with CRC after curative surgery. In this study, a subset analysis of patients with stage III CRC revealed that patients with high PDGFC protein expression had a poor clinical outcome irrespective of the use of adjuvant chemotherapy after surgery (data not shown). Intensive adjuvant chemotherapy may be applicable for patients with CRC and high PDGFC expression even if they lack other conventional risk factors for recurrence. Multivariate analysis indicated that lymph node metastasis and PDGFC protein expression are independent prognostic factors for recurrence. Therefore, application of PDGFC expression together with a prognostic indicator such as TNM classification might improve the prediction of prognosis in patients with CRC. Furthermore, although there is no evidence of synergy between cytotoxic chemotherapy and molecular targeted drugs for adjuvant therapy after curative surgery, multiple targeted RTK inhibitors may have efficacy against PDGFC-overexpressing CRC because PDGFC may play a role in the activation of RTK pathways according to some reports. Moreover, because PDGFC is overexpressed mainly in cancer cells whereas it is not expressed or only weakly expressed in normal cells, it may be a novel target for cancer treatment without adverse effects on normal cells.
Conclusion
In conclusion, overexpression of PDGFC in CRCs was correlated with recurrence and poor prognosis. PDGFC may be a predictive biomarker of CRC recurrence and a target for the treatment of this disease.
